Boston Scientific — Oct 22, 2025 release

BOSTON SCIENTIFIC CORPORATION Q4 and FY 2025 GUIDANCE RECONCILIATIONS (Unaudited) Net Sales Q4 2025 Estimate (Low) (High) Full Year 2025 Estimate Reported growth 14.5   % 16.5   % ~20.0% Impact of foreign currency fluctuations (2.0) % (2.0) % ~(1.0)% Operational growth 12.5   % 14.5   % ~19.0% Impact of certain acquisitions/divestitures (1.5) % (1.5) % ~(3.5)% Organic growth 11.0   % 13.0   % ~15.5% Earnings per Share Q4 2025 Estimate Full Year 2025 Estimate (Low) (High) (Low) (High) GAAP results $ 0.48   $ 0.52   $ 1.97   $ 2.01   Amortization expense 0.13  0.13  0.51  0.51  Acquisition/divestiture-related net charges (credits) 0.04  0.04  0.15  0.15  Restructuring and restructuring-related net charges (credits) 0.07  0.05  0.22  0.20  Other adjustments 0.04  0.04  0.18  0.18  Adjusted results $ 0.77   $ 0.79   $ 3.02   $ 3.04   Amounts may not add due to rounding. Use of Non-GAAP Financial Measures To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less